The Surgeon General Nominee Ate Magic Mushrooms. The Senate Had Questions.

March 1, 2026

A Stanford-trained surgeon walked into the United States Senate last Wednesday. Got grilled about magic mushrooms.

Not opioids. Not fentanyl. Not the fact that antidepressant prescriptions tripled since 2000 while depression rates climbed right alongside them. Nope. Senator Susan Collins — Republican, Maine, 73 years old — held up a copy of Good Energy by Dr. Casey Means and demanded to know why Trump's pick for surgeon general told Americans to "explore intentional, guided psilocybin therapy."

I watched the clip four times. First time I caught Collins saying "concerned" like the word itself was contaminated. Second time I caught Means pivoting — smooth, rehearsed — to "the science is still emerging." Third time I noticed neither woman mentioned a single study. Fourth time it hit me.

Psilocybin just became a confirmation hearing topic for the top public health job in America. Not fringe. Center stage. Under oath. February 25, 2026. Mark it.

The Quote That Lit the Fuse

In her 2024 bestseller Good Energy — co-authored with brother Calley, who now advises RFK Jr. at HHS — Means wrote:

"If you feel called, I also encourage you to explore intentional, guided psilocybin therapy. Strong scientific evidence suggests that this psychedelic therapy can be one of the most meaningful experiences of life for some people, as they have been for me."

She wrote for me. Let that land. The woman who might become America's top doctor disclosed personal psilocybin use. In a published book. On bookstore shelves. Then sat before the Senate Health Committee and took questions about it from Susan Collins.

Collins asked if she stood by those words. Means recalibrated fast. "What I would say as a private citizen is, in many cases, different than what I would say as a public health official."

Smart politics. Terrible science. The data does not demand retreat. It demands a spine.

What She Could Have Said

Compass Pathways finished its second positive Phase 3 trial for COMP360 on February 17th. Synthetic psilocybin. Treatment-resistant depression. Over 800 patients across COMP005 and COMP006. The 25 mg dose hit a 3.8-point MADRS reduction versus active control at Week 6. Thirty-nine percent of patients — these are people who already blew through SSRIs, SNRIs, talk therapy, sometimes electroconvulsive — showed meaningful improvement from one or two sessions.

No daily pill. No six-week ramp-up. One session. Six months of improvement.

No classic psychedelic has hit two Phase 3 primary endpoints. Not one. Ever. In the entire history of psychopharmacology.

Sandeep Nayak, director at Johns Hopkins Center for Psychedelic and Consciousness Research, said the trial design directly answers the FDA concerns that killed Lykos's MDMA application in 2024. Few participants had prior psychedelic exposure. Active comparator — low-dose psilocybin — instead of sugar pill everyone can see through. Meticulous adverse event documentation. This is not some uncontrolled retreat center situation.

Robin Carhart-Harris built psychedelic research at Imperial College London from scratch before moving to UCSF. He said COMP360 approval is "a matter of time." That man does not say things he cannot defend in peer review.

And psilocybin is not sitting alone out there. Terence Ching at Yale ran psilocybin-for-OCD. Reunion Neuroscience scored Breakthrough Therapy designation for luvesilocin — psilocybin analog — targeting postpartum depression. Current PPD treatment? Sixty-hour IV drip. Thirty-four thousand dollars. MindMed has MM120, an LSD formulation, in Phase 3 for generalized anxiety. AbbVie — Humira company, three hundred billion market cap — wrote a $1.2 billion check for bretisilocin from Gilgamesh Pharmaceuticals. These are not vibes. These are balance sheets.

The BMJ published a full psychedelic medicine review February 23rd. That journal started in 1840. When the BMJ weighs in, the skeptics get quiet.

So Collins waving around a DEA fact sheet about nausea and hallucinations? Either uninformed or performing. Pick one.

The Washington Circus

This part is genuinely bizarre. RFK Jr. stands before Congress and says psychedelics have "tremendous advantage in clinical settings." Makary at FDA promises fast review. Then October hits and somebody — unnamed, no public explanation — pulls COMP360 off the Commissioner's National Priority Voucher list. Would have shaved months off FDA review. STAT News broke it February 4th.

Kennedy out front with pom-poms. Faceless bureaucrat yanking the emergency brake behind the curtain. Same government, opposite signals.

Meanwhile DEA — the drug warriors — bumped the 2026 psilocybin production quota 67 percent. Why? Research labs could not get enough material. The agency that classifies psilocybin as Schedule I ("no currently accepted medical use") is manufacturing more of it because medical researchers keep running out.

I am a mycologist in Leipzig. I have been studying fungi since I was dissecting Amanita phalloides in my mother's kitchen at fourteen. I have seen a lot of institutional absurdity. This particular flavor — where the machine contradicts itself this loudly — usually means the old framework is cracking. Something different is pushing through.

Australia prescribes psilocybin. Legal since July 2023. Authorized psychiatrists, clinical settings, depression and PTSD. Germany — my neighbor — launched compassionate-use programs at Mannheim and Berlin. Czech Republic legalized medical psilocybin January 1st this year. The BMJ review cites Phase 2 studies on psilocybin for combined depression and alcohol use disorder. MDMA for PTSD plus alcohol dependence. Real-world populations. Not cherry-picked healthy volunteers.

America is debating whether a surgeon general candidate should have eaten mushrooms three years ago while the rest of the developed world moves forward.

Why the Mushroom People Should Pay Attention

Most of you on ShrooMap are not holding your breath for FDA scheduling decisions. You already take lion's mane with breakfast. You already stacked cordyceps before your workout Tuesday.

But here is why the Means hearing ripples outward.

When a US senator says "mushroom" on C-SPAN — even dismissively — people google. Some find psilocybin trials. Some find lion's mane memory studies. Some find reishi. Some end up right here, reading this.

The biology connects more tightly than the politics suggest. Psilocybin hits 5-HT2A receptors. Triggers BDNF. Promotes dendritic spine growth in the prefrontal cortex. Rewires circuits that got stuck in depressive loops. Lion's mane works a parallel track — NGF stimulation through hericenones and erinacines — different receptors, same destination. Neuroplasticity. New connections. Brain remodeling.

If you take lion's mane every morning, you are feeding the same fundamental process that makes psilocybin work in those Phase 3 trials. Different intensity. Different legality. Same biological principle.

And stacking — lion's mane plus cordyceps for mitochondrial energy, reishi for HPA axis modulation and sleep architecture — you are hitting multiple systems.

Igor's Honest Assessment

Means had a platform. Fifty million people could have heard her explain that psilocybin has more rigorous Phase 3 data than most antidepressants had at approval. That Hopkins, Yale, NYU, UCSF, and Imperial College published peer-reviewed work on this compound for over a decade. That the mechanism — serotonin 2A agonism driving neuroplastic rewiring — is well-characterized. That clinical safety data from over 800 Phase 3 participants shows mostly mild to moderate adverse events.

She chose "the science is still emerging." A sentence that sounds responsible and means absolutely nothing. All science is emerging. General relativity is emerging. She ducked when the data supported standing.

But — and I keep coming back to this — five years ago nobody would have asked the question. Ten years ago psilocybin was a punchline at parties. Now it is a Senate hearing issue, a billion-dollar acquisition target, and the subject of BMJ clinical reviews. The Overton window cracked because researchers like Carhart-Harris and Matthew Johnson and Roland Griffiths — who we lost in 2023, still hurts — spent entire careers producing data so bulletproof that even a senator waving a DEA pamphlet cannot pretend it away forever.

Means probably gets confirmed. When she does, America's surgeon general will be someone who ate psilocybin mushrooms and published a book about it. First time ever. Even if she never breathes the word psilocybin in office, the precedent sits there. Open.

If you are curious about the broader mushroom ecosystem and where the science stands across species, our complete guide to functional mushrooms covers what is legal, what is studied, and what actually works.

The mushroom kingdom just walked into Congress. Awkwardly. Controversially. But it walked in.

— Dr. Igor Busse, PhD
Leipzig, Germany

FAQ

Did the surgeon general nominee actually use psilocybin?

Yes. Dr. Casey Means disclosed personal psilocybin use in her 2024 book Good Energy, writing that guided psilocybin therapy was among "the most meaningful experiences of life" for her. She confirmed this at her Senate confirmation hearing on February 25, 2026.

Is psilocybin legal in the United States?

Psilocybin remains a Schedule I controlled substance federally. Oregon and Colorado have legalized regulated access through supervised service programs. Clinical trials using synthetic psilocybin (like Compass Pathways' COMP360) operate under FDA authorization. Compass plans to file for FDA approval between October and December 2026.

How does psilocybin relate to functional mushrooms like lion's mane?

Both target neuroplasticity through different molecular pathways. Psilocybin activates 5-HT2A serotonin receptors, triggering BDNF release and dendritic spine growth. Lion's mane stimulates nerve growth factor (NGF) through hericenones and erinacines. Different mechanisms, same biological outcome: brain remodeling and new neural connections.

What were the results of the latest COMP360 Phase 3 trial?

The COMP006 trial (announced February 17, 2026) showed that two 25 mg doses of COMP360 produced a statistically significant 3.8-point reduction on the MADRS depression scale versus active control at Week 6. Thirty-nine percent of treatment-resistant patients showed clinically meaningful improvement, with effects persisting over 26 weeks.